News

This combo is approved for adults with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer. The clearance applies when an estrogen receptor 1 (ESR1) mutation is

The funding was led by BVF Partners, with participation from new investors Deep Track Capital and Perceptive Advisors. Existing backers included Catalio Capital Management, Cooley, Eli Lilly and

The agreement gives Médunik Canada immediate responsibility for Diacomit’s sales, marketing, and medical affairs activities throughout the country. It aims to leverage Médunik Canada’s network and rare disease

The contract allows Qilu Pharmaceutical to use the antibody, which was developed through Biocytogen’s RenNano platform, in its research and development (R&D) activities focused on neuroscience therapeutics. It

The deal allows Novartis to exercise multiple options for exclusive global rights to develop subcutaneous versions of several of its products employing the berahyaluronidase alfa enzyme, also known

The agreement will see Aitia apply its REFS technology to build Gemini Digital Twins (GDTs) of neurological conditions to identify potential new therapeutic targets and biomarkers. Ono Pharmaceutical

The partnership aims to integrate Weave Bio’s AI tools with Takeda’s regulatory experience to streamline workflows within the regulatory process. The joint effort began with the use of

This marks the first FDA-approved treatment for ET in nearly 30 years. The approval is based on data from the global Phase III SURPASS ET trial, which demonstrated

These proceeds will support the planned and ongoing studies of Kazia’s lead investigational therapy, paxalisib, in triple-negative breast cancer, hormone receptor positive/human epidermal growth factor receptor 2 negative